Compare Cassava Sciences Inc (FLNA) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Raymond James Financial, Inc. — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Raymond James Financial, Inc. trades at $158.28 (market cap $30.51B). The key difference: Raymond James Financial, Inc. is far larger — about 774.4× Cassava Sciences Inc's market cap, and Raymond James Financial, Inc. pays a 1.36% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Raymond James Financial, Inc. for 75 Days on average.
| FLNA | RJF | |
|---|---|---|
Market Cap | $39.40M | $30.51B |
Volume | 759,018 | 1,206,253 |
Sector | Health | Financials |
52-Week High | $4.64 | $181.18 |
52-Week Low | $0.68 | $140.89 |
Typical Hold Time | 37 Days | 75 Days |
Enterprise Value | -$43.28M | $24.37B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.
The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.
RJF trades at $158.28, up 0.63% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.14 exceeding expectations. Revenue grew to $13.84B in 2025, and net income margin stands at 15.37%. Recent news highlights executive leadership changes and a declared dividend of $0.54 per share payable in October 2026.
The outlook is mixed: analyst consensus is a 'Hold' with a $184 price target, implying potential upside, but technical indicators signal near-term caution. Key risks include rising expenses and market volatility, while growth drivers include wealth management expansion and investment banking recovery. The stock presents a balanced opportunity with solid fundamentals offset by technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
